-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cusatuzumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cusatuzumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cusatuzumab in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
Ventricular Tachycardia – Drugs In Development, 2023
Global Markets Direct’s, ‘Ventricular Tachycardia - Drugs In Development, 2023’, provides an overview of the Ventricular Tachycardia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ventricular Tachycardia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Tachycardia (Tachyarrhythmias) – Drugs In Development, 2023
Global Markets Direct’s, ‘Tachycardia (Tachyarrhythmias) - Drugs In Development, 2023’, provides an overview of the Tachycardia (Tachyarrhythmias) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tachycardia (Tachyarrhythmias), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Atrial Fibrillation – Drugs In Development, 2023
Global Markets Direct’s, ‘Atrial Fibrillation - Drugs In Development, 2023’, provides an overview of the Atrial Fibrillation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atrial Fibrillation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Myelofibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myelofibrosis - Drugs In Development, 2023’, provides an overview of the Myelofibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drugs In Development, 2023’, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Huntington Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Huntington Disease - Drugs In Development, 2023’, provides an overview of the Huntington Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Huntington Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABBV-932 in Generalized Anxiety Disorder (GAD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABBV-932 in Generalized Anxiety Disorder (GAD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-932 in Generalized Anxiety Disorder (GAD) Drug Details: ABBV-932...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASN-004 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASN-004 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASN-004 in Colorectal Cancer Drug Details: ASN-004 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XmAb-968 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XmAb-968 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.XmAb-968 in Relapsed Acute Myeloid Leukemia Drug Details:XmAb-698 (AMG-424) is under...